SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Collage with halftone hands putting puzzle together. Teamwork concept vector pop art retro style illustration. Partnership and relationship design element for infographic, poster, website
Rare diseases
FDA Signs Off on Neurogene’s ‘Best-Case Scenario’ Pivotal Study Design for Rett Syndrome
The pivotal trial for Neurogene’s Rett syndrome gene therapy makes use of baseline controls and a rigorous endpoint that could help ensure a broader label for the drug product, if approved, according to analysts.
July 1, 2025
 · 
2 min read
 · 
Tristan Manalac
Megaphone with stethoscope isolated on orange background. 3d illustration
Obesity
Protagonist Enters Obesity Fray With Triple-G Pill, Eyeing 2026 Clinical Start
With PN-477, Protagonist is directly going up against Eli Lilly, which is advancing retatrutide, also a triple-G agonist, in a Phase II trial.
July 1, 2025
 · 
2 min read
 · 
Tristan Manalac
Wooden blocks with arrow and error icon. Delays and disruptions, stop the process, critical error concept
Lymphoma
Pfizer Ends Mid-Stage Trial for CD47 Blood Cancer Drug, Citing Recruitment Problems
Pfizer insists that the discontinuation of the Phase II study was due to recruitment difficulties and was not linked to maplirpacept’s safety or efficacy.
July 1, 2025
 · 
2 min read
 · 
Tristan Manalac
Bright pink background with a trolley for the supermarket. Modern web template for promotion design. Seamless geometric pattern. Abstract art.
Mergers & acquisitions
June’s Busy Buyout Binge Bolsters M&A Stats for H1
Big Pharmas like Eli Lilly, Sanofi and Novartis headed back to the dealmakers table multiple times, with 32 total deals counted across the industry for the first half.
July 1, 2025
 · 
4 min read
 · 
Annalee Armstrong
Photo collage of happy businesswoman funny person building stairs way success achieve goals to increase income isolated on white background.
Cancer
Amgen’s Antibody Improves Overall Survival in Phase III Gastric Cancer Test
In a detail-thin announcement, Amgen said that adding bemarituzumab to chemotherapy improved overall survival, though analysts pledged to wait for more data on safety and tolerability before assessing the drug.
June 30, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Contemporary art collage, female palms in the orange circle, a bag of money. Concept of business and finance.
Mergers & acquisitions
AbbVie Plunks Down $2.1B for Capstan and Its Novel CAR T Therapies
The all-cash buyout, which gives AbbVie access to Capstan Therapeutics’ in vivo edited CAR T therapy for B cell–mediated autoimmune diseases, adds to a growing sense of momentum in M&A, according to BMO Capital Markets.
June 30, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Illustration showing businessman bringing personal items in box stock
Layoffs
BMS Continues New Jersey Layoffs, Bringing Yearly Total to Nearly 900
BMS is letting go of 68 employees in Lawrenceville, New Jersey. The pharma has now cut over 1,000 employees there since April 2024 as part of its cost-cutting measures.
June 30, 2025
 · 
1 min read
 · 
Angela Gabriel
Brain with lightning, brainstorming vector icon vector icon
Alzheimer’s disease
Alzheimer’s Deals Surged 780% After Leqembi, Kisunla Broke Approval Stalemate
The rise of monoclonal antibodies brought back hope for stalling or reversing the devastating neurodegenerative disease. Big Pharma has taken notice with a handful of high-value deals, GlobalData reports.
June 30, 2025
 · 
2 min read
 · 
Annalee Armstrong
Brain with pills, Alzheimer awareness day, dementia diagnosis, Parkinson disease, memory loss disorder, damaged mind
Alzheimer’s disease
INmune Crashes After Missing Cognitive Target in Phase II Alzheimer’s Trial
Digging into a prespecified analysis for the mid-stage study, INmune Bio identified some clinical and biological benefits of its TNF inhibitor in patients with early Alzheimer’s disease who have at least two biomarkers of inflammation.
June 30, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS